Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

doi:10.3748/wjg.v24.i2.179

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (19960)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series.

Item

Count

PDF

2133

WORD

307

HTML

14307

Figures (1-7)

256

Sum=17003

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1336

Download

1621

Sum=2957

Jan 14, 2018 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (108)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jan 14, 2018; 24(2): 179-194
Published online Jan 14, 2018. doi: 10.3748/wjg.v24.i2.179

Full Size Figure Download Figure

Figure 3 Histomorphological effects of liraglutide, obeticholic acid, and elafibranor treatment in DIO-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Citation: Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 179-194
URL: https://www.wjgnet.com/1007-9327/full/v24/i2/179.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i2.179